title: Prevalence of dyslipidemic risk factors in hemodialysis and CAPD patients.
abstract: BACKGROUND
  Dyslipidemic factors obviously contribute to the high cardiovascular risk in dialysis patients but are often an underestimated problem. Therefore, we determined the prevalence of dyslipidemic factors in a large group of unselected hemodialysis (N = 564) and CAPD (N = 168) patients.
  
  
  METHODS
  We used the recently published recommendations of the Medical Experts Group concerning cardiovascular risk factors for the categorization of dyslipidemic factors. These were total cholesterol>200 mg/dL, low-density lipoprotein (LDL) cholesterol>100 mg/dL, high-density lipoprotein (HDL) cholesterol <40 mg/dL, triglycerides>180 mg/dL, and Lp(a)>30 mg/dL.
  
  
  RESULTS
  CAPD patients had, in sum, a markedly worse lipid profile when compared with HD patients. They had higher frequencies of elevated total cholesterol (67% vs. 34%), triglycerides (47% vs. 28%), and Lp(a) concentrations (37% vs. 30%) when compared with HD patients. In both patient groups, about two thirds of the patients had LDL cholesterol above 100 mg/dL and HDL cholesterol below 40 mg/dL. When we analyzed the total frequency of dyslipidemic factors, we observed that the CAPD group included a markedly higher number of patients with three or four concurrent dyslipidemic factors than HD patients (P < 0.001). Furthermore, we analyzed apolipoprotein A-IV (apoA-IV), which was recently shown to be associated with cardiovascular disease, and which was about twice as high in both patient groups when compared with controls (P < 0.001).
  
  
  CONCLUSIONS
  Dyslipidemic risk factors are highly prevalent in dialysis patients, and the concomitant occurrence of several risk factors in a given patient is more often observed in CAPD than HD patients.
authors.affiliation: Institute of Medical Biology and Human Genetics, University of Innsbruck, Innsbruck, Austria. Florian.Kronenberg@uibk.ac.at
authors.forename: Florian
authors.initials: F
authors.lastname: Kronenberg
authors.forename: Arno
authors.initials: A
authors.lastname: Lingenhel
authors.forename: Ulrich
authors.initials: U
authors.lastname: Neyer
authors.forename: Karl
authors.initials: K
authors.lastname: Lhotta
authors.forename: Paul
authors.initials: P
authors.lastname: König
authors.forename: Martin
authors.initials: M
authors.lastname: Auinger
authors.forename: Martin
authors.initials: M
authors.lastname: Wiesholzer
authors.forename: Helene
authors.initials: H
authors.lastname: Andersson
authors.forename: Hans
authors.initials: H
authors.lastname: Dieplinger
mesh_terms: D000328:Adult; D000368:Aged; D001054:Apolipoproteins A / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000453:epidemiology*; D007676:Kidney Failure, Chronic / Q000453:epidemiology* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000706:statistics & numerical data*; D015995:Prevalence; D006435:Renal Dialysis / Q000706:statistics & numerical data*; D012307:Risk Factors; D014280:Triglycerides / Q000097:blood
chemical_list: D001054:Apolipoproteins A; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D014280:Triglycerides; C022205:apolipoprotein A-IV